Tag:
Fragile X
Latest Headlines
Latest Headlines
Study: Asuragen's molecular Dx better at Fragile X detection
Asuragen is celebrating encouraging clinical data, suggesting one of its molecular diagnostic tests is better than existing standards of care in determining how likely a woman will have a child with Fragile X syndrome--a genetic cause of autism spectrum disorders and other intellectual disabilities.
Genentech plucks rights to Afraxis drug assets in $187M deal
Primarily known for its work on Fragile X, a well-known autism target, Afraxis says that the giant Roche subsidiary will pay up to $187.5 million in milestones and an undisclosed upfront in order to develop the compounds for a "novel target."
Roche, Seaside join forces against autism and Fragile X
Roche has tapped assets from biotech startup Seaside Therapeutics to advance pioneering treatments for Fragile X syndrome and autism spectrum disorders.
Drug tackles Fragile X/autism symptoms in mice
Scientists at F. Hoffman-La Roche in Switzerland and the Picower Institute for Learning at the Massachusetts Institute of Technology believe they've found a new compound that reverses most Fragile X-related symptoms in adult mice.
Roche headlines autism alliance
A European research effort led by Roche ( $RHHBY ) and others to tackle autism spectrum disorders nailed down $38.7 million in financing for what will be a massive, 5-year project seeking to come up with new diagnostic and treatment options.
NIH buddies with Afraxis to escort Fragile X program through "valley of death"
San Diego-based Afraxis is getting some key support from the National Institutes of Health as it journeys through the dreaded "valley of death" with an experimental program for Fragile X syndrome--a
Roche begins Ph II Fragile X studies
Swiss drugmaker Roche has begun a Phase II study of a candidate to treat Fragile X syndrome, a condition that is the most common cause of autism yet identified, the FRAXA Research Foundation
Autism drugs head into human clinical trials
Experimental drugs aimed at correcting three rare conditions linked with autism are beginning early-stage human trials. These therapies are targeted at Rett syndrome, fragile X , and tuberous
